99 HIGH STREET, 30TH FLOOR, BOSTON, MA
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Other Events
Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Amended material disclosure
Megan Sniecinski Appointed Chief Operating Officer at Praxis Precision Medicines
Praxis Precision Medicines, Inc. Announces Underwritten Offering of 2.2M Shares
Praxis Precision Medicines Reports Cash and Securities of $925 Million
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report